当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

Abstract：

PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance. PATIENTS AND METHODS:SIAH2 expression was measured with quantitative Real-Time-PCR (qRT-PCR) in 1205 primary breast tumor specimens and related to disease outcome. The functional role of SIAH2 was determined in human breast cancer cell lines ZR-75-1, ZR/HERc, and MCF7. Cell lines were treated with estrogen (E2), anti-estrogen ICI164.384 or epidermal growth factor (EGF). Moreover, MCF7 was treated with ICI164.384 after silencing SIAH2 expression. RESULTS:SIAH2 was not prognostic in 603 lymph node negative patients who had not received adjuvant systemic therapy. In multivariate analysis of ER-positive tumors of 235 patients with recurrent disease, SIAH2 as continuous variable, significantly predicted first-line tamoxifen treatment failure (OR = 1.48; P = 0.05) and progression-free survival (PFS) (HR = 0.79; P = 0.007). Furthermore, in primary breast cancer patients treated with adjuvant tamoxifen, SIAH2 predicted metastasis-free survival (MFS) (HR = 0.73; P = 0.005). In vitro experiments showed that SIAH2 silencing in MCF7 cells resulted in resistance to ICI164.384-treatment when compared with mock silenced cells (P = 0.008). Interestingly, in ZR cells transfected with EGFR (ZR/HERc), SIAH2 expression was induced by E2 but downregulated by EGF. CONCLUSION:In primary breast tumor specimens as well as in vitro low SIAH2 levels associated with resistance to endocrine therapy. Moreover, SIAH2 expression showed an opposite regulation by E2 and EGF.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

doi

10.1007/s10549-008-0125-z

subject

Has Abstract

pub_date

2009-07-01 00:00:00

pages

263-71

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

116

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.

    abstract：PURPOSE:Genomic studies have revealed that genomic aberrations play important roles in the progression of this disease. The aim of this study was to evaluate the associations between clinical survival outcomes of the clonality and subclonality status of driver genes in breast cancer. METHODS:We performed an integrated...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05153-8

    authors： Lan Y,Zhao E,Luo S,Xiao Y,Li X,Cheng S

    更新日期：2019-05-01 00:00:00

  • Staging efficacy of breast cancer with sentinel lymphadenectomy.

    abstract：:Seventy-two patients underwent dye-guided or dye- and gamma probe-guided sentinel lymphadenectomy (SLND) followed by complete axillary lymph node dissection (ALND). The results of imprint cytology, frozen sections, and permanent sections of the sentinel lymph node (SLN) were compared to each other and to the histologi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006268426526

    authors： Noguchi M,Bando E,Tsugawa K,Miwa K,Yokoyama K,Nakajima K,Michigishi T,Tonami N,Minato H,Nonomura A

    更新日期：1999-09-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract：:Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1946-8

    authors： Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期：2012-07-01 00:00:00

  • Availability of prior mammograms affects incomplete report rates in mobile screening mammography.

    abstract：PURPOSE:Mobile mammography can improve access to screening mammography in rural areas and underserved populations. We evaluated the frequency of incomplete reports in mobile mammography screening and the relationships between prior mammograms and recall rates. METHODS:The frequency of incomplete mammogram reports, the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4861-4

    authors： Roubidoux MA,Shih-Pei Wu P,Nolte ELR,Begay JA,Joe AI

    更新日期：2018-10-01 00:00:00

  • Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas.

    abstract：:Estrogen receptor alpha (ERalpha) activity is regulated by phosphorylation at several sites. Recently several antibodies specific for individual phosphorylated sites within ERalpha have became available. Such antibodies potentially provide invaluable tools to gain insight into the relevance in vivo of phosphorylated E...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0267-z

    authors： Skliris GP,Rowan BG,Al-Dhaheri M,Williams C,Troup S,Begic S,Parisien M,Watson PH,Murphy LC

    更新日期：2009-12-01 00:00:00

  • Dietary intake from birth through adolescence in relation to risk of benign breast disease in young women.

    abstract：PURPOSE:Nutritional factors during different periods in life impact breast cancer risk. Because benign breast disease (BBD) is a well-established risk factor for breast cancer, we investigated childhood nutrition from birth through age 14 year and subsequent BBD. METHODS:A prospective cohort study of 9031 females, 9-1...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05323-8

    authors： Berkey CS,Tamimi RM,Willett WC,Rosner B,Hickey M,Toriola AT,Lindsay Frazier A,Colditz GA

    更新日期：2019-09-01 00:00:00

  • Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients.

    abstract：:Our aim was to develop an accurate diagnostic system using gene expression analysis by means of DNA microarray for prognosis of node-negative and estrogen receptor (ER)-positive breast cancer patients in order to identify a subset of patients who can be safely spared adjuvant chemotherapy. A diagnostic system comprisi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1145-z

    authors： Naoi Y,Kishi K,Tanei T,Tsunashima R,Tominaga N,Baba Y,Kim SJ,Taguchi T,Tamaki Y,Noguchi S

    更新日期：2011-08-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • Delayed versus immediate exercises following surgery for breast cancer: a systematic review.

    abstract：BACKGROUND:Seroma formation, wound healing and fluid drainage are a concern for both surgeons and patients. Excessive fluid production can result in seroma formation, and inadequate drainage of seromas is known to cause infection, pain, discomfort and longer periods of hospitalisation. Postoperative exercises given to ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-004-4727-9

    authors： Shamley DR,Barker K,Simonite V,Beardshaw A

    更新日期：2005-04-01 00:00:00

  • Phase II study of amonafide in advanced breast cancer.

    abstract：:Twenty-eight patients with advanced breast cancer refractory to prior hormone and/or first-line chemotherapy (with or without anthracycline drugs) were treated with the investigational agent amonafide at a dose of 800 mg/m2 intravenously over 3 hours repeated every 4 weeks. Five objective tumour responses of 5.0 month...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01833358

    authors： Scheithauer W,Dittrich C,Kornek G,Haider K,Linkesch W,Gisslinger H,Depisch D

    更新日期：1991-12-01 00:00:00

  • Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.

    abstract：:Taxanes are being used for the treatment of breast cancer. However, cancer cells frequently develop resistance to these drugs with the subsequent recurrence of the tumor. MDA-MB-231 and T-47D breast cancer cell lines were used to assess the effect of paclitaxel treatment on apoptosis and cell cycle, the possible mecha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1864-9

    authors： Flores ML,Castilla C,Ávila R,Ruiz-Borrego M,Sáez C,Japón MA

    更新日期：2012-06-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract：:The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666043

    authors： Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期：1995-01-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract：:Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666210

    authors： LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期：1994-01-01 00:00:00

  • Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.

    abstract：UNLABELLED:Taxanes and anthracyclines improve the outcome of early breast cancer, although the benefit is limited to a small proportion of patients and are toxic. We prospectively looked for predictors of response to these drugs. EXPERIMENTAL DESIGN:Four cycles of doxorubicin (75 mg/m²) or docetaxel (100 mg/m²) were c...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-011-1461-y

    authors： Martin M,Romero A,Cheang MC,López García-Asenjo JA,García-Saenz JA,Oliva B,Román JM,He X,Casado A,de la Torre J,Furio V,Puente J,Caldés T,Vidart JA,Lopez-Tarruella S,Diaz-Rubio E,Perou CM

    更新日期：2011-07-01 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract：:Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-012-2118-1

    authors： Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期：2012-07-01 00:00:00

  • Minor role for BRCA2 (exon11) and p53 (exon 5-9) among Sudanese breast cancer patients.

    abstract：:A cohort of 20 breast cancer patients from the Sudan was tested for germ line and somatic mutation in their BRCA2 exon 11 as well as the main conserved area of the p53 tumor suppressor gene. The results indicate that both regions may play a limited role in the pathogenesis of breast cancer in those patients. The fact ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1013807830329

    authors： Masri MA,Abdel Seed NM,Fahal AH,Romano M,Baralle F,El Hassam AM,Ibrahim ME

    更新日期：2002-01-01 00:00:00

  • Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.

    abstract：:The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of 125I EGF to tumor plasma membrane preparations. Tumor wit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666480

    authors： Bolla M,Chedin M,Colonna M,Marron-Charrière J,Rostaing-Puissant B,Pasquier D,Panh MH,Winckel P,Chambaz EM

    更新日期：1994-01-01 00:00:00

  • Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases.

    abstract：:Circulating CA 15-3 antigen levels were evaluated in patients with benign diseases and breast cancer patients with no clinical evidence of disease after surgery (NED). Patients with breast cancer NED were followed for tumor recurrence or death during a median of 12.9 months (range 1 to 25 months). CA 15-3 and carcinoe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01806524

    authors： Colomer R,Ruibal A,Genollá J,Rubio D,Del Campo JM,Bodi R,Salvador L

    更新日期：1989-03-01 00:00:00

  • Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer.

    abstract：:Steroid receptor coactivators are important in regulating the function of the receptors in endocrine organ development and in cancers, including breast. Androgen receptor (AR) coactivator ARA70, was first identified as a gene fused to the ret oncogene and later characterized as an AR coactivator. We previously reporte...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1131-5

    authors： Wu X,Chen F,Sahin A,Albarracin C,Pei Z,Zou X,Singh B,Xu R,Daniels G,Li Y,Wei J,Blake M,Schneider RJ,Cowin P,Lee P

    更新日期：2011-07-01 00:00:00

  • Feature extraction via composite scoring and voting in breast cancer.

    abstract：:Identification and characterization of tumor subtypes using gene expression profiles of triple negative breast cancer patients. Microarray data of four breast cancer studies were pooled and evaluated. Molecular subtype classification was performed using random forest and a novel algorithm for feature extraction via co...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2177-3

    authors： Koch M,Hanl M,Wiese M

    更新日期：2012-08-01 00:00:00

  • Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

    abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01833345

    authors： Reid AD,Horobin JM,Newman EL,Preece PE

    更新日期：1992-01-01 00:00:00

  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.

    abstract：:Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-009-0520-0

    authors： Sergentanis TN,Economopoulos KP

    更新日期：2010-05-01 00:00:00

  • The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

    abstract：:The goal of the present study was to evaluate the role of the tyrosine kinase receptor fibroblast growth factor-1 (FGFR1) and its ligand, the fibroblast growth factor 2 (FGF2) in determining the response to chemoradiotherapy of breast cancers. S14 was a phase II neoadjuvant study carried out at the Institut Curie that...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2027-3

    authors： Massabeau C,Sigal-Zafrani B,Belin L,Savignoni A,Richardson M,Kirova YM,Cohen-Jonathan-Moyal E,Mégnin-Chanet F,Hall J,Fourquet A

    更新日期：2012-07-01 00:00:00

  • Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting.

    abstract：OBJECTIVES:To validate the newly proposed American Joint Committee on Cancer (AJCC) prognostic staging system for breast cancer. METHODS:Surveillance, epidemiology, and end results (SEER) database (2010-2014) was accessed. Cumulative incidence function was conducted (through assessment of sub-distribution hazard) acco...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4577-x

    authors： Abdel-Rahman O

    更新日期：2018-02-01 00:00:00

  • Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.

    abstract：PURPOSE:This study aimed to examine the prevalence and trends of breast cancer-related risk factors and characteristics in premenopausal underweight Korean women according to birth year cohort. METHODS:Socioeconomic and breast cancer-related risk factors were investigated in 13,415 premenopausal women using nationwide...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-05091-x

    authors： Kim JH,Yoon KH,Hur H,Park S,Kim JY,Park HS,Kim SI,Cho YU,Park BW

    更新日期：2019-04-01 00:00:00

  • Measures of energy balance and mammographic density in the Nurses' Health Study.

    abstract：:Mammographic density is a strong risk factor for breast cancer; however the mechanism that underlies this association is unclear. We hypothesized that measures of energy balance early in life and in adulthood may be associated with mammographic density. We conducted a cross-sectional analysis of 1,398 women in the Nur...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9631-7

    authors： Samimi G,Colditz GA,Baer HJ,Tamimi RM

    更新日期：2008-05-01 00:00:00

  • Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

    abstract：PURPOSE:To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before high dose chemotherapy and to study the pharmacokinetic interactions of these three drugs. PATIENTS AND METHOD...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1011945623464

    authors： Conte PF,Gennari A,Donati S,Salvadori B,Baldini E,Bengala C,Pazzagli I,Orlandini C,Danesi R,Fogli S,Del Tacca M

    更新日期：2001-07-01 00:00:00

  • Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death.

    abstract：PURPOSE:Complementary and alternative medicines (CAMS) are frequently used by patients with breast cancer and their use may be related to the presence of psychosocial distress. The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-3779-1

    authors： Rakovitch E,Pignol JP,Chartier C,Ezer M,Verma S,Dranitsaris G,Clemons M

    更新日期：2005-03-01 00:00:00

  • Tests for detecting recurrent disease in the follow-up of patients with breast cancer.

    abstract：:In 141 postmenopausal node-positive patients with primary breast cancer, routine biochemical markers (alkaline phosphatase, gamma-glutamyl transpeptidase, carcinoembryonic antigen), and chest x-ray, in combination with history and clinical examination, have been performed at 3 monthly intervals for at least 2 years. S...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01807283

    authors： Mansi JL,Earl HM,Powles TJ,Coombes RC

    更新日期：1988-07-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00